Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 4/20 | 0.44 |
| ▸ | POLQ | O75417 | 8/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6815067 | 0.84 | TAAR1 (0.52) | DAOCES2IDO1POLQTAAR1 | |
| SCHEMBL6018761 | 0.83 | CES2 (0.46) | DAOCES2IDO1TAAR1TSHR | |
| SCHEMBL1538523 | 0.83 | DAO (0.49) | DAOCES2IDO1POLQ | |
| SCHEMBL1993639 | 0.81 | CES2 (0.52) | DAOCES2IDO1POLQ | |
| SCHEMBL147650 | 0.79 | DAO (0.46) | DAOCES2IDO1POLQ | |
| SCHEMBL4590973 | 0.79 | ALDH1A1 (0.47) | IDO1TAAR1TSHRMAPK1 | |
| SCHEMBL4416164 | 0.79 | POLQ (0.51) | DAOCES2IDO1POLQ | |
| SCHEMBL13958202 | 0.79 | DAO (0.46) | DAOCES2IDO1POLQ | |
| SCHEMBL109671 | 0.79 | IDO1 (0.65) | IDO1 | |
| SCHEMBL1873922 | 0.79 | DAO (0.46) | DAOCES2IDO1POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | claimed |
| CN-119735529-A | Benzamide compound and application thereof in preparation of sensitizer of pseudomonas aeruginosa inhibitor | 海南大学 | 2025-04-01 | — | — | CN | disclosed |
| WO-2024196958-A2 | COMPOUNDS FOR RESTORING SUSCEPTIBILITY TO BETA-LACTAM ANTIBIOTICS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2024-09-26 | — | — | WO | disclosed |
| CN-118221644-A | Pyrrolidine derivative, composition and application thereof | 上海京新生物医药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-114380753-B | Aryl or heteroaryl substituted quinoxaline-2, 3-diamine compound and antibacterial application thereof | 中国医学科学院药物研究所 | 2024-02-27 | — | — | CN | disclosed |
| WO-2022195522-A1 | INHIBITORS OF ANO6 AND THEIR USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022157686-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-07-28 | — | — | WO | disclosed |
| CN-114380753-A | Aryl or heteroaryl substituted quinoxaline-2, 3-diamine compound and antibacterial application thereof | 中国医学科学院药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-8501769-B2 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1654235-B1 | 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1036785-B1 | Process for the preparation of bis(trifluoromethyl)benzylamines | BAYER AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
| US-6476267-B1 | Process for producing aromatic primary amine by low-pressure | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6376712-B2 | REDUCTION OF THE CORRESPONDING OXIME COMPOUND | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-23 | — | — | US | disclosed |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-31 | — | — | US | disclosed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | disclosed |
| US-6137011-A | CATALYTICALLY HYDROGENATINING BISTRIFLUOROMETHYLBENZONITRILE, IN PRESENCE OF RANEY COBALT,ALIPHATIC ETHER, AND AMMONIA TO FORM BISTRIFLUOROMETHYLBENZYL-AMINE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-24 | — | — | US | disclosed |
| EP-1036785-A1 | Process for the preparation of bis(trifluoromethyl)benzylamines | Bayer Aktiengesellschaft (DE) | 2000-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | DAO 2997/4885CES2 3942/4885IDO1 1232/4885 |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | DAO 2908/4885CES2 3712/4885IDO1 1192/4885 |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | MAOB, CYP2F1, AGL | DAO 45/4885CES2 449/4885IDO1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.